We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement.
- Authors
McGuire, Amy L.; Cohen, I. Glenn; Sisti, Dominic; Baggott, Matthew; Celidwen, Yuria; Devenot, Neşe; Gracias, Sabrina; Grob, Charles; Harvey, Ifetayo; Kious, Brent; Marks, Mason; Mithoefer, Michael; Nielson, Elizabeth; Öngür, Dost; Pallas, Alexandra; Peterson, Andrew; Schenberg, Eduardo E.; Summergrad, Paul; Waters, Brett; Williams, Monnica T.
- Abstract
Key Points: Question: What does ethical integration of psychedelic medicines look like? Findings: This consensus statement reports 20 points of consensus on managing 5 ethical issues related to the upcoming integration of psychedelic medicines into clinical practice and identifies areas for further research and deliberation. Meaning: As psychedelic medicines near government approval, it is essential to plan ahead for their ethical use. This consensus statement identifies key ethics and policy issues for the future integration of psychedelic therapies into clinical practice. Importance: As government agencies around the globe contemplate approval of the first psychedelic medicines, many questions remain about their ethical integration into mainstream medical practice. Objective: To identify key ethics and policy issues related to the eventual integration of psychedelic therapies into clinical practice. Evidence Review: From June 9 to 12, 2023, 27 individuals representing the perspectives of clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists convened at the Banbury Center at Cold Spring Harbor Laboratory. Prior to the meeting, attendees submitted key ethics and policy issues for psychedelic medicine. Responses were categorized into 6 broad topics: research ethics issues; managing expectations and informed consent; therapeutic ethics; training, education, and licensure of practitioners; equity and access; and appropriate role of gatekeeping. Attendees with relevant expertise presented on each topic, followed by group discussion. Meeting organizers (A.L.M., I.G.C., D.S.) drafted a summary of the discussion and recommendations, noting points of consensus and disagreement, which were discussed and revised as a group. Findings: This consensus statement reports 20 points of consensus across 5 ethical issues (reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping), with corresponding relevant actors who will be responsible for implementation. Areas for further research and deliberation are also identified. Conclusions and Relevance: This consensus statement focuses on the future of government-approved medical use of psychedelic medicines in the US and abroad. This is an incredibly exciting and hopeful moment, but it is critical that policymakers take seriously the challenges ahead.
- Subjects
MENTAL illness drug therapy; HEALTH services accessibility; POST-traumatic stress disorder; DIVERSITY &; inclusion policies; RESPECT; PROFESSIONAL ethics; TOUCH; HALLUCINOGENIC drugs; UNITED States. Food &; Drug Administration; CERTIFICATION; DRUG approval; EXPERIENCE; INFORMED consent (Medical law); PROFESSIONAL licenses; SOCIAL boundaries; MENTAL depression
- Publication
JAMA Network Open, 2024, Vol 7, Issue 6, pe2414650
- ISSN
2574-3805
- Publication type
Article
- DOI
10.1001/jamanetworkopen.2024.14650